Early Entecavir Treatment for Chronic Hepatitis B with Severe Acute Exacerbation

Autor: Tzung-Jiun Tsai, Huey-Shyan Lin, Hsien-Chung Yu, Po-Hung Chiang, Wen-Chi Chen, Wei-Lun Tsai, Ping-I Hsu, Hoi-Hung Chan, Feng-Woei Tsay, Huay-Min Wang, Jin-Shiung Cheng, Kwok-Hung Lai
Rok vydání: 2014
Předmět:
Zdroj: Antimicrobial Agents and Chemotherapy. 58:1918-1921
ISSN: 1098-6596
0066-4804
Popis: A previous study found that lamivudine, if started early enough, may improve the chance of survival in chronic hepatitis B virus (HBV) with severe acute exacerbation (SAE). The aim of this study was to investigate the effect of early entecavir treatment before the bilirubin level exceeds 20 mg/dl for chronic HBV with SAE. Consecutive patients with chronic HBV with SAE and a serum bilirubin level of P = 1.000). If only patients who started antiviral treatment before serum bilirubin level rose to more than 15 mg/dl were included, 3 patients (8.3%) in the entecavir group and 3 patients (3.0%) in the lamivudine group died ( P = 0.189). If only patients with an HBV DNA level higher than 10 5 copies/ml and a bilirubin level lower than 15 mg/dl were included, 5 out of 40 patients (12.5%) in the entecavir group died and 1 out of 59 patients (1.7%) in the lamivudine group died. Multivariate analysis found that entecavir treatment was associated with more mortality than lamivudine ( P = 0.035). Early entecavir treatment in patients with high viral load is associated with more short-term mortality than lamivudine for chronic HBV with severe acute exacerbation.
Databáze: OpenAIRE